INTENSITY THERAPEUTICS, INC.
Nasdaq: INTSBiological Products, (No Diagnostic Substances) · Entity-resolved by Clous
Key financials
Short interest & fails
Short volume (FINRA Reg SHO) · fails-to-deliver (SEC) · borrow fee (broker securities-lending feed) — via the Clous API.
AI business summary — latest 10-K
Summary
The filing details Intensity Therapeutics' equity activities for the fiscal year ending December 31, 2025, including public offerings, at-the-market (ATM) offerings, registered direct offerings, and the issuance of common stock and warrants.
What it means
The company is actively utilizing multiple capital-raising strategies, including various stock offerings and warrants, to increase its liquidity and equity base.
What to watch
Monitor the execution of ATM offering agreements and the exercise of Series B1 and B2 common warrants.
Generated from public filings · not investment advice
| Concept | FY2023-12-31 | FY2024-12-31 | FY2025-12-31 | YoY | % rev |
|---|---|---|---|---|---|
| Net Income | -$10.54M | -$16.27M | -$11.61M | +28.7% | — |
| Total Assets | $17.3M | $4.78M | $14.1M | +194.8% | — |
| Equity | $13.16M | $2.92M | $11.88M | +307.0% | — |
| Operating Cash Flow | -$7.21M | -$15.22M | -$9.23M | +39.3% | — |
| Shares Outstanding | — | — | 2.54M | — | — |
Get this entity — and 970.89K+ others — programmatically.
One clean JSON shape, resolved IDs, MCP-native. Query the same data behind this page.
GET /v1/entities?cik=0001567264